Cantor Fitzgerald Predicts Weaker Earnings for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for Cabaletta Bio in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($1.38) per share for the year, down from their previous estimate of ($1.22). The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 21st. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.04).

A number of other equities analysts have also recently issued reports on CABA. Wells Fargo & Company lowered their target price on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, April 1st. Guggenheim boosted their price target on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Morgan Stanley decreased their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, April 1st. UBS Group dropped their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Cabaletta Bio in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $20.33.

Cabaletta Bio Price Performance

CABA stock traded down $0.03 during trading on Wednesday, reaching $1.75. 689,980 shares of the company were exchanged, compared to its average volume of 1,555,935. The company has a market capitalization of $88.80 million, a price-to-earnings ratio of -0.81 and a beta of 2.72. The company has a 50-day moving average of $1.37 and a two-hundred day moving average of $2.12. Cabaletta Bio has a twelve month low of $0.99 and a twelve month high of $13.50.

Institutional Investors Weigh In On Cabaletta Bio

A number of large investors have recently made changes to their positions in CABA. Acadian Asset Management LLC boosted its position in shares of Cabaletta Bio by 36.5% in the 1st quarter. Acadian Asset Management LLC now owns 682,670 shares of the company's stock worth $942,000 after purchasing an additional 182,406 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Cabaletta Bio during the first quarter valued at approximately $102,000. Almitas Capital LLC bought a new stake in Cabaletta Bio in the 1st quarter worth approximately $509,000. Comerica Bank grew its holdings in shares of Cabaletta Bio by 2,292.1% in the first quarter. Comerica Bank now owns 41,599 shares of the company's stock worth $58,000 after acquiring an additional 39,860 shares during the period. Finally, Callan Family Office LLC purchased a new stake in shares of Cabaletta Bio during the 1st quarter valued at about $58,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.